Vertex Pharmaceuticals
A page on organisations in our medical research coverage, part of our health reporting, alongside the 6 reports filed on it so far.
Setara Biosciences launches with $90 million for rare disease drug
A new biotech company, Setara Biosciences, has launched with $90 million to develop a therapy for Charcot-Marie-Tooth disease and overactive bladder...
Arrowhead's ARO-MAPT shows major tau reduction in early trial
Arrowhead Pharmaceuticals' RNAi drug ARO-MAPT reduced tau protein by an average of 73% in healthy volunteers, demonstrating significant target...
ADARx files for IPO to fund three clinical-stage siRNA medicines
ADARx Pharmaceuticals has filed for an initial public offering to raise funds for advancing its pipeline of siRNA therapies.
Novartis, Ionis heart drug fails in major Phase 3 trial
Novartis and Ionis Pharmaceuticals' experimental drug pelacarsen failed to reduce heart attacks, strokes or death in a Phase 3 study of over 8,000...
Ionis' Zanvastro Wins First FDA Approval for Alexander Disease
The FDA has approved Ionis Pharmaceuticals' Zanvastro, the first treatment for the rare neurological disorder Alexander disease.
Teva bids $57.5M for bankrupt BioXcel assets
Teva Pharmaceuticals has been named the stalking horse bidder to acquire BioXcel Therapeutics' neuroscience portfolio for $57.5 million upfront.